Overall Survival Rate and Recurrence Free Survival Rate in Breast Sarcoma Patients: Single Center 5-Years Retrospective Study

Background: Overall survival rates of breast sarcoma patient in 10 years was 62%. 5-years and 10-year recurrence-free survival was 47% and 42%, respectively. The differences survival rate of breast sarcoma patient depend on age, stage, chemotherapy history and radiotherapy history that correlates with the natural history of the disease or well known as prognostic factor of the patient. The purposes of this study is to identify different prognostic factors and their impact to overall survival rates and recurrence-free survival rates on breast sarcoma patient.

Methods: This study was conducted on all patients of all breast sarcoma patients in 2015 - 2016 who were treated by the Subdivision of Surgical Oncology at Dr. Moewardi General Hospital Surakarta (21 patients). The required data were retrieved from medical records. Overall survival rate and recurrent survival rate were analyzed using Kaplan Meier and bivariate analysis using log-rank analysis.

Results: The results of the log-rank analysis of the prognostic factors of age, histopathology (phylloides tumor and angiosarcoma tumor), stage, chemotherapy (administration of doxorubicin), radiotherapy, systemic disease, herbal treatment, and duration of the patient before taking any medication. With the overall survival rate showed P-values of 0.681, 0.007, 0.037, 0.034, 0.505, 0.891, 0.012, and 0.903, respectively. The results of the log-rank analysis of the prognosis factors with the recurrence-free survival rate showed that the P-values were 0.962, < 0.001, 0.059, 0.097, 0.537, 0.596, 0.021, and 0.274, respectively.

Conclusions: There was a significant difference of patient’s overall survival rate in prognostic factors of chemotherapy history, histopathology, use of herbal treatment, and stage of the sarcoma. Histopathology, herbal treatment, and duration of the patient before taking any medication.showed a significant patient’s recurrence-free survival rate difference.